Stocksigma LogoStocksigma Logo

Welcure Drugs Reports FY26 Financials with Significant Auditor Disclosures

Welcure Drugs & Pharmaceuticals approved corrected standalone results for the year ended 31st Mar'26, superseding its 29th May'26 filing

Welcure Drugs Reports FY26 Financials with Significant Auditor Disclosures

Welcure Drugs & Pharmaceuticals Ltd · Others (Uncategorized) · 02 Nov 2026, 11:15 pm

Welcure Drugs Reports FY26 Financials with Significant Auditor Disclosures Welcure Drugs & Pharmaceuticals approved corrected standalone results for the year ended 31st Mar'26, superseding its 29th May'26 filing. FY26 revenue surged to ₹38,952.44 lakh versus ₹2,455.00 lakh in FY25, driven entirely by the agriculture segment. However, the company posted a net loss of ₹567.08 lakh compared to a profit of ₹217.01 lakh in FY25. Statutory auditors issued an unmodified opinion with substantial emphasis of matters, noting unconfirmed supplier advances of ₹15,126.13 lakh, unverifiable sales invoices lacking e-way bills, and unverified inventory of ₹143,52.36 lakh.

Original exchange filing (PDF)

More announcements from Welcure Drugs & Pharmaceuticals Ltd

All Welcure Drugs & Pharmaceuticals Ltd announcements